NDAOPHTHALMICSUSPENSION/DROPS
Approved
Apr 2013
Lifecycle
Peak
Competitive Pressure
8/100
Clinical Trials
8
Mechanism of Action
Carbonic Anhydrase Inhibitors
Pharmacologic Class:
Carbonic Anhydrase Inhibitor
Clinical Trials (5)
Safety and Efficacy of SIMBRINZA® BID as an Adjunctive to DUOTRAV®
Started Jun 2016
173 enrolled
Open-angle GlaucomaOcular Hypertension
24-hr Intraocular Pressure Control With SIMBRINZA ®
Started May 2016
162 enrolled
Glaucoma
SIMBRINZA® Suspension BID as an Adjunctive to Prostaglandin Analogue (PGA)
Started Aug 2015
290 enrolled
Open-Angle GlaucomaOcular Hypertension
A Study of Simbrinza™ Therapy in Patients With Open-Angle Glaucoma or Ocular Hypertension
Started Nov 2014
150 enrolled
Open-Angle GlaucomaOcular Hypertension
Comparison of Combigan Two Times Daily (BID) Versus Simbrinza Three Times Daily (TID)
Started Aug 2014
43 enrolled
GlaucomaOcular Hypertension
Loss of Exclusivity
LOE Date
Oct 30, 2030
56 months away
Patent Expiry
Oct 30, 2030
Company
Alcon
FORT WORTH, TX